Parkinsonian gait improvement through vibratory stride parameter feedback.
Paul Kirsch, Miriam Helbig, Dominic Rupar and 2 others
Stride length and heel strike angle both improved when a vibratory insole buzzed at the moment gait deteriorated, with gains comparable to the patients' own medication.
The improvements were small, and no falls outcome was measured.
Key findings
1Vibratory feedback increased average stride length by 3.44 cm and heel strike angle by 1.15 degrees compared with no stimulation. The stride-length gain was 63% of the medication effect and the heel-strike-angle gain was 107% of the medication effect in the same model.
2Vibration delivered at random time points (not contingent on gait deterioration) produced values between the control and feedback walks that were not significantly different from either, and did not improve stride length or heel strike angle in the first stride after stimulation.
3The feedback effect was consistent across medication states, Hoehn and Yahr stages, and the two independent cohorts (no significant interactions). Patients rated the device as useful (7.2 out of 10 in cohort 1; 5.8 out of 10 in cohort 2), with no significant difference between feedback and random vibration ratings.
Still to come
How it was doneWhat they foundWhat it means for PTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Small samples: 13 and 19 completers, with small subgroups within Hoehn and Yahr stages, so the absence of interactions may reflect low power rather than true consistency. Each walking bout lasted about 13 minutes; the authors note the device is intended for longer use but this has not been tested. Effect sizes were small (Cohen's d 0.16–0.20), and no minimal clinically important difference exists for stride length or heel strike angle, so the clinical meaning of the gains is uncertain. No falls outcome was measured; the paper does not show that the gait improvement translates into fewer falls. An observer filmed the participants throughout, which may have influenced gait (Hawthorne effect). The inclusion of the random-vibration condition in cohort 2 may have reduced the perceived distinctiveness of the feedback condition, as the authors themselves note. The insole prototype was developed by a commercial company (Novapace, Darmstadt), and the device is not yet available for clinical use.
Declared interests
Funded by Johann Wolfgang Goethe-Universität, Frankfurt am Main. The insole prototype was developed by Novapace, Darmstadt, Germany. No other conflicts of interest are declared in the supplied text.
The easy way to misread this
Do not read the 'comparable to medication' framing as evidence of a large, clinically transformative effect. The effect sizes were small (Cohen's d 0.16–0.20), the random-vibration condition was not significantly different from either the feedback or the no-stimulation walk, the improvement was confined to the first stride after the buzz, and no falls outcome was measured. The device has only been tested for about 13 minutes per walk, and long-term use, habituation, and real-world fall reduction remain unproven.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →